stockrow
Saturday 7 November 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
- EPS
- −18.6%
- Free cash flow
- −64.8%
Quarter to September 2026, against a year earlier
24.48
0.76
+3.20%
Follow RAPP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 20 | 20 | 20 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (11) | (35) | (78) | (111) | (150) | +118.7% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (11) | (35) | (78) | (111) | (150) | +118.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (13.71) | (23.10) | (3.78) | (2.86) | (3.17) | (40.7%) | ||||||
| Cash flow | — | — | — | — | — | — | (4.17) | (18.05) | (3.13) | (2.25) | (2.53) | (18.6%) | ||||||
| Capex | — | — | — | — | — | — | (6.80) | (1.09) | (0.12) | (0.02) | 0.00 | (86.8%) | ||||||
| Free cash flow | — | — | — | — | — | — | (10.97) | (19.13) | (3.24) | (2.26) | (2.53) | (40.9%) | ||||||
| Book value | — | — | — | — | — | — | 25.10 | 93.59 | 14.73 | 12.45 | 8.19 | (20.8%) | ||||||
| Shares, m | — | — | — | — | — | — | 1 | 2 | 21 | 39 | 45 | +268.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (3) | (27) | (65) | (87) | (121) | +199.9% | |||||
| Capex | — | — | — | — | — | — | (5) | (2) | (2) | (1) | 0 | (51.1%) | ||||||
| Free cash flow | — | — | — | — | — | — | (9) | (29) | (67) | (88) | (121) | +117.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 30 | 142 | 301 | 480 | 387 | +153.0% | |||||
| Net debt | — | — | — | — | — | — | (31) | (148) | (305) | (491) | (395) | +150.6% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | 20 | 141 | 305 | 485 | 391 | +191.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (37.20) | (33.30) | (26.95) | (31.55) | (27.0) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | (123,593.75) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 194.90 | (55.97) | (28.22) | (33.33) | (28.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 26 | 69 | 84 | — | +79.7% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Latest quarter Mar 2026 · fundamentals updated 6 Nov 2026
Rapport Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MNKD MannKind Corporation | $1.2B | — (loss-making) | — (loss-making) | +24.04% (above 0%: growing) | n/m | −267.69% (below 0%: shrinking) | 0.00% | (2.14%) | Compare |
| AVLN Avalyn Pharma Inc. | $1.2B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.2B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VOR Vor Biopharma Inc. | $1.2B | — (loss-making) | — | — | n/m | −47.59% (below 0%: shrinking) | 0.00% | — | Compare |
| RAPP Rapport Therapeutics, Inc. | $1.1B | — (loss-making) | — | — | n/m | −64.75% (below 0%: shrinking) | 100.00% | 0.00% | |
| SGP SpyGlass Pharma, Inc. | $1.1B | — (loss-making) | — | — | n/m | −100.49% (below 0%: shrinking) | — | 0.00% | Compare |
| VSTM Verastem, Inc. | $1.1B | — (loss-making) | — (loss-making) | +113.59% (above 0%: growing) | n/m | +24.50% (above 0%: growing) | 0.00% | (313.28%) | Compare |
| SPTX Seaport Therapeutics, Inc | $1.1B | — (loss-making) | — | — | n/m | −43.81% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $1.2B | — | — | +113.59% | — | −43.81% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Ownership
Directors and executive officers, together
12.48%
Entities affiliated with Third Rock Ventures
16.95%
Entities affiliated with Fidelity
11.48%
ARCH Venture Fund XII, L.P.
7.80%
Entities affiliated with Cormorant Asset Management, LP
6.33%
One or more entities advised by Capital Research and Management Company
5.44%
BlackRock, Inc.
5.01%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement